Compare

Amgen vs Eli Lilly and

MonkScore ranges and fundamentals, side by side

Key facts

Amgen and Eli Lilly and: key facts

  • In fiscal 2025, Amgen Inc. reported revenue of $36.7B and net income of $7.7B.
  • In fiscal 2025, Eli Lilly and Company reported revenue of $65.2B and net income of $20.6B.
  • Amgen Inc.'s revenue grew 9.1% a year from fiscal 2021 to fiscal 2025.
  • Eli Lilly and Company's revenue grew 23.2% a year from fiscal 2021 to fiscal 2025.
  • Amgen Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • Eli Lilly and Company's free cash flow was positive in 4 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 June 2026, Amgen Inc. reported revenue of $38.1B and net income of $8.7B.
  • In the twelve months to 30 September 2026, Eli Lilly and Company reported revenue of $86.5B and net income of $27.6B.

Side by side

Amgen and Eli Lilly and, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureAmgen Inc.NASDAQ:AMGNEli Lilly and CompanyNYSE:LLY
MonkScore
MonkScore range90–100as of October 202690–100as of October 2026
Sector rank65 of 628 in Healthcare22 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralDrug Manufacturers - General
Latest fiscal year
Revenue$36.7BFY 2025$65.2BFY 2025
Net income$7.7BFY 2025$20.6BFY 2025
Free cash flow$8.1BFY 2025$9.0BFY 2025
Operating cash flow$10.0BFY 2025$16.8BFY 2025
Total debt$54.6BFY 2025$42.5BFY 2025
Cash$9.1BFY 2025$7.2BFY 2025
Last 12 months
Revenue$38.1Bto 30 June 2026$86.5Bto 30 September 2026
Net income$8.7Bto 30 June 2026$27.6Bto 30 September 2026
Free cash flow$10.2Bto 30 June 2026$19.7Bto 30 September 2026
Operating cash flow$12.5Bto 30 June 2026$30.6Bto 30 September 2026
Total debt$57.3Bto 30 June 2026$49.5Bto 30 September 2026
Cash$14.0Bto 30 June 2026$4.9Bto 30 September 2026

MonkStreet provides research, not investment advice.